Simian Foamy Virus Pseudotypes of Vesicular Stomatitis Virus:
Production and Use in Sero-epidemiological Investigations (Accepted 2 November 1981) 
SUMMARY
Simian foamy virus (SFV) pseudotypes of vesicular stomatitis virus have been successfully produced and their host range characterized. The availability of these pseudotypes has permitted the development of a rapid, quantitative assay to measure neutralizing antibody titres to SFV that has proved useful in a sero-epidemiological study.
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Although a wide variety of enveloped viruses have been demonstrated to be capable of producing pseudotypes when cells are coinfected with vesicular stomatitis virus (VSV) (Zavada, 1976) , similar VSV pseudotypes have never been reported with simian foamy viruses (SFV). The isolation and characterization (Schnitzer, 1981) of a virus (SFV-314) identical with SFV type 1 from tissues infiltrated by malignant cells in a stump-tailed monkey (Macaca arctoides) presented the opportunity to investigate the potential for pseudotype production, with the aim of undertaking sero-epidemiological studies made possible by the development of a rapid, quantitative neutralization assay utilizing SFV pseudotypes of VSV. Production of SFV-314 pseudotypes of VSV was performed following procedures similar to those previously described . Briefly, 8155 cell (dog thymus) cultures (Schnitzer, 1979) infected with SFV-314 and demonstrating extensive cytopathic effect (>50 % of surface area being vacuolated syncytia) were infected at a multiplicity of 0.1 to 1.0 p.f.u/cell with wild-type VSV and incubated at 37 °C overnight. The supernatant fluid was clarified and then assayed for VSV infectivity on a range of indicator cells after incubation with either phosphate-buffered saline or anti-VSV serum.
After treatment with anti-VSV serum a residual fraction of VSV infectivity could always be demonstrated in harvests of progeny virus from VSV-infected 8155 cells showing extensive SFV cytopathic effect (Fig. 1) . That this did not represent incomplete neutralization of VSV was demonstrated by the fact that additional treatment of such samples with further anti-VSV serum failed to reduce the residual VSV infectivity (data not shown). Furthermore, complete neutralization of a similar amount of progeny virus harvested after VSV infection of SFV-free 8155 cells could be demonstrated with the same concentrations of anti-VSV serum (Fig. 1) .
Characterization of the pseudotypes produced was accomplished by examination of their host range for penetration and their ability to be neutralized by known immune sera. Using a wide range of assay cells it was possible to demonstrate the presence of cell receptors for the SFV antigens expressed on the surface of the VSV pseudotypes and to measure the efficiency with which the pseudotypes were capable of penetrating the cell membrane. The host range for penetration defined in this manner for the SFV isolated in this study (SFV-314) is shown in Fig. 1 . No cell type tested was resistant to penetration and even avian cells (C/E; Schnitzer, 1979) could be demonstrated to have receptors for this virus. The sensitivity of this type of assay, however, was clearly greatest when performed with monkey cells (Vero; Schnitzer & G6ncz61, 1979) .
Further characterization of the pseudotypes produced was directed towards defining the identity of the envelope antigens by use of specific-immune sera ( (Schnitzer et al., 1977) ]. The titre of VSV prior to neutralization was greater than l0 s p.f.u./ml for all harvests assayed simultaneously on the same cells.
neutralization of the VSV infectivity of the pseudotype fraction could be demonstrated after treatment of this virus with either the reference immune serum against SFV type 1 or serum obtained from the diseased animal at autopsy. Neither serum resulted in neutralization of VSV harvested from SFV-314 uninfected cells, ruling out a non-specific antiviral effect. Immune sera against other serotypes of SFV as well as all other control sera failed to result in neutralization of the SFV pseudotypes of VSV (Table I a) . Quantitative neutralization assays of serum utilizing SFV-314 pseudotypes of VSV were performed in a manner similar to that described previously with other virus pseudotypes of VSV (Schnitzer et al., 1977) . Utilizing this method, neutralization titres of the reference immune serum to SFV type 1 and the serum obtained from the diseased monkey were found to be 160 and 640 respectively (Table I a) . Because the production of SFV-314 pseudotypes of VSV permitted the development of a rapid quantitative assay for presence of neutralizing activity against SFV-314 in sera, a sero-epidemiological survey was implemented to investigate evidence for exposure to this SFV in those humans and monkeys in close contact with the diseased animal. Sera were collected on various occasions after the death of the diseased animal; no earlier sera were available. Five people had been known to have had prolonged and intimate contact with the ill monkey and serum was obtained from four. In addition, sera from 11 monkeys in the same colony were also available for testing. Determination of neutralizing titres of these sera demonstrated no evidence for infection by SFV-314 in any of the humans tested. In contrast, however, all monkeys had detectable neutralizing activity in their serum, several in titres significantly higher than that seen in the serum obtained from the diseased monkey itself (Table 1 b) .
The importance of SFV for the production and/or maintenance of malignancies within its own host species is not known. The fact that SFV can penetrate a wide variety of cell types (see above) coupled with the fact that it does contain enzymic machinery permitting synthesis of a DNA form (Parks et al., 1971) , gives it the potential for initiating cellular alterations without resulting in productive replication and means that it may still be of pathogenic importance despite its failure to elicit an immunological response in heterologous hosts. Because sera were not available from either the diseased animal or other monkeys in the colony prior to the termination of the disease process, it was impossible to determine if there had been a spread of this agent within the primate community, and if so, the temporal Schnitzer (1979) . § Monkey no. 12 is the diseased animal investigated in this report.
sequence of such events. However, sero-epidemiological studies addressing such issues have previously been undertaken by numerous investigators (for review, see Hooks & Gibbs, 1975) utilizing conventional techniques (neutralizing antibody titres) and tend to confirm the findings reported above. Utilizing the SFV pseudotypes of VSV, it should be possible to initiate similar sero-epidemiological studies of a prospective nature within primate colonies and to examine human contacts as well, with the aim of defining more precisely the method of spread of this virus and its possible role in acquired or naturally occurring disease.
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